NLRP3 and Myocardial fibrosis: In addition, astragaloside IV (AS-IV), the Astragalus membranaceus major bioactive component, was able to reduce myocardial fibrosis and myocardial hypertrophy, which may be attributed to decreased ROS levels and the suppression of the NLRP3/Caspase-1/GSDMD pyroptosis pathway after AS-IV treatment [78].